OraSure Technologies(NASDAQ) OSUR

OraSure Technologies, Inc. makes simple tests for serious health conditions. These tools help people get fast medical results at home. The company also makes kits for scientists to collect samples.

What Is in the Kit?

• Diagnostics: Rapid tests for diseases like HIV (human immunodeficiency virus), Hepatitis C, and Ebola used at clinics; accounted for 63% of net revenues in the three months ended June 30, 2026.
• Sample Management Solutions: Tools for collecting and stabilizing genetic material for genomics, which is the study of genes; represented 32% of net revenues in the three months ended June 30, 2026.
• In-Home Tests: Consumer-friendly versions of HIV and COVID-19 screening kits sold over-the-counter for private use.
• Genomic Services: Laboratory processing for genetic samples used in academic research, ancestry testing, and animal health studies.

Strategic Moves and New Clearances

• Acquired BioMedomics, Inc. in November 2025 to add SickleSCAN revenue streams to the diagnostic portfolio.
• Received FDA clearance in June 2026 for the Colli-Pee at-home urine collection device for sexually transmitted infections.
• Secured Emergency Use Authorization in July 2026 for a second-generation Ebola rapid antigen test with increased sensitivity.
• Developed a rapid molecular self-test for Chlamydia and Gonorrhea, though the initial regulatory submission was withdrawn in July 2026 for updates.

The Edge in Easy Testing

The company uses proprietary technology to collect medical samples through oral fluid and urine without using needles. It also partners with government agencies like the Biomedical Advanced Research and Development Authority to develop tests for global health emergencies.

A Look at the Numbers

• Consolidated net revenues were $30.6 million for the three months ended June 30, 2026, down 2% year over year.
• Operating income reached $5.4 million for the three months ended June 30, 2026, compared to an $18.0 million loss in the prior year period.
• Cash and cash equivalents totaled $160.6 million as of June 30, 2026.
• Research and development expenses decreased 17% to $9.4 million for the three months ended June 30, 2026.
• Sales of Diagnostics products rose 1% to $19.4 million for the three months ended June 30, 2026.

Bottom Line

OraSure has transitioned from a pandemic-focused testing provider to a broader developer of chronic disease and genomic sample tools. Its recent shift toward at-home collection kits and molecular diagnostics supports its evolution into a diversified health management business.